CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are the mainstay of treatment for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The gene discussed is ESR1; the disease is breast carcinoma.